MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress

September 15-18, 2022. Madrid, Spain.

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
  • P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial

    C. Olanow, K. Kieburtz, P. Litman, H. Friedman, S. Oren (Sarasota, USA)

  • Pain and Disability Outcomes in Hemiparetic Patients Naive to Botulinum Toxins With Upper and Lower Limb Spasticity Treated With OnabotulinumtoxinA: Insights From the ASPIRE Study

    G. Bavikatte, A. Esquenazi, W. Jost, A. Barichich, E. Duarte, M. Schwartz, T. Musacchio, G. Francisco (Liverpool, United Kingdom)

  • Pain and Disability Outcomes in Hemiparetic Patients With Post-Stroke Spasticity: Exploratory Analysis of the ASPIRE Study

    G. Bavikatte, G. Francisco, W. Jost, A. Barichich, E. Duarte, M. Schwartz, T. Musacchio, A. Esquenazi (Liverpool, United Kingdom)

  • Pain reduction in adult patients with limb spasticity following a single incobotulinumtoxinA injection: an analysis of pooled data from phase 2 and 3 studies

    J. Wissel, A. Camões-Barbosa, G. Comes, M. Althaus, A. Scheschonka, D. Simpson (Potsdam, Germany)

  • Painful arm spasms after remote electrical injury: focal epilepsy begets causalgia-dystonia?

    J. Cohen, J. Wilkinson (Philadelphia, USA)

  • Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report

    M. Gultekin, S. Benli (Kayseri, Turkey)

  • Pallidal beta activity correlates with stimulation-induced bradykinesia in dystonia patients

    R. Lofredi, U. Scheller, A. Mindermann, J. Krauss, A. Saryyeva, GH. Schneider, A. Kühn (Berlin, Germany)

  • Pallidal Deep Brain Stimulation for Treatment of Poststroke Hemichorea

    D. Yoo, CK. Park, TB. Ahn (Seoul, Republic of Korea)

  • Pallidal firing rate and alpha oscillations correlate with the severity of clinical symptoms in patients with dystonia

    U. Semenova, R. Medvednik, A. Tomskiy, V. Popov, A. Sedov (Moscow, Russian Federation)

  • Pan India Registry for Progressive Supranuclear Palsy (PAIR-PSP)

    P. Kukkle, R. Gupta, S. Desai, S. Mehta, D. Joshi, N. Kumar, R. Kandadai, L. Sahoo, A. Mukherjee, V. Paramanandam, S. Murugan, D. Kp, S. Sundaram, R. Rajan, R. Menon, K. Shetty, P. Samson, S. Krishnan, M. Deshmukh, P. Wadia, C. Sandeep, P. Aggarwal, S. Bhowmick, H. Kumar, A. Biswas, V. Goyal, S. Seshagiri, R. Borgohain, V. Ramprasad (Bangalore, India)

  • Paraneoplastic Cerebellar Ataxia Due To Ovarian Teratoma: A Case Report

    R. Zouari, C. Jeridi, F. Nabli, MZ. Saeid, S. Blel, S. Ben Sassi (tunis, Tunisia)

  • Parkin deficiency impairs mtDNA dynamics and propagates inflammation

    K. Wasner, S. Smajić, J. Ghelfi, S. Delcambre, C. Prada-Medina, E. Knappe, G. Arena, P. Mulica, G. Agyeah, A. Rakovic, I. Boussaad, K. Badanjak, J. Ohnmacht, J. Gérardy, M. Takanashi, J. Trinh, M. Mittelbronn, N. Hattori, C. Klein, P. Antony, P. Seibler, M. Spielmann, S. Pereira, A. Grünewald (Belvaux, Luxembourg)

  • Parkinson disease with LRRK2 mutation associated with upper motor neuron dysfunction

    A. Rodriguez-Sanz, S. Serrano (MADRID, Spain)

  • Parkinson`s disease in Pandemic Covid

    S. Galbineanu, A. Ailene (Brasov, Romania)

  • Parkinson’s disease caregiver burden in rural India

    S. Desai, D. Desai, I. Prashnani (Anand, India)

  • Parkinson’s disease and nucleus basalis of Meynert integrity: Cognition and everyday function

    N. Slater, R. Shoorangiz, G. Hall-Mcmaster, A. Harris, L. Livingston, S. Grenfell, K. Clifford, T. Anderson, T. Melzer, J. Dalrymle-Alford (Christchurch, New Zealand)

  • Parkinson’s Disease and Psychosocial Impact: Anxiety, Depression and Positive Symptoms

    O. Kaczmarek, S. Baek, A. Sethi, A. Stolarczyk, B. Bumstead, B. Anand, M. Buhse, M. Zarif, M. Gudesblatt (Patchogue, USA)

  • Parkinson’s disease symptom asymmetry at disease onset corresponds to low-beta power asymmetry in the subthalamic nucleus

    A. Buijink, F. Torrecillos, M. Stam, D. Piña-Fuentes, A. Pogosyan, C. Wiest, R. de Bie, P. Schuurman, G. Tinkhauser, H. Tan, M. Beudel (Amsterdam, Netherlands)

  • Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management

    O. Kaczmarek, S. Baek, A. Sethi, A. Stolarczyk, B. Bumstead, M. Buhse, M. Zarif, B. Anand, M. Gudesblatt (Patchogue, USA)

  • Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey

    F. de Renzis, L. Graham, M. Meinders (Orpington, United Kingdom)

  • Parkinson’s Progression Marker Initiative (PPMI) Online identifies people with features of prodromal Parkinson’s Disease through online questionnaires

    E. Brown, L. Chahine, D. Alonso, C. Coffey, R. Dobkin, T. Foroud, M. Korell, A. Lorenzo, C. Marras, W. Poewe, T. Sherer, A. Siderowf, T. Simuni, E. Tolosa, J. Valverde Twiggs, D. Weintraub, S. Chowdhury, K. Marek, C. Tanner (San Francisco, USA)

  • Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD)

    E. Brown, D. Alonso, L. Chahine, C. Coffey, R. Dobkin, M. Korell, A. Lorenzo, C. Marras, W. Poewe, T. Sherer, A. Siderowf, T. Simuni, E. Tolosa, J. Valverde Twiggs, D. Weintraub, S. Chowdhury, K. Marek, C. Tanner (San Francisco, USA)

  • Parkinsonian disorders may have different pain features.

    SY. Kang, YH. Sung (Hwaseong, Republic of Korea)

  • Parkinsonism-hyperpyrexia as a rare consequence of deep brain stimulator malfunction in patients with Parkinson’s disease

    M. Castela, M. Estrada, S. Bruck, E. San Martín, J. álvarez, C. Fernández, J. Carriles, B. Aragoneses, A. Ayala, E. Liébana, B. López, J. Gil, A. Antón, P. Arroyo, AK. Mendoza (Oviedo, Spain)

  • Paroxysmal dystonia with phenotypic variability in ECHS1 mutation twin carriers

    G. Bonato, M. Nosadini, S. Andretta, A. Suppiej, A. Leon, S. Sartori, M. Carecchio (Padua, Italy)

  • Paroxysmal Musician’s Dyskinesia

    J. Hislop, D. Shpiner, J. Margolesky (Miami, USA)

  • Patient Advisory Boards: A Model for Patient Engagement in Parkinson’s Disease Comparative Effectiveness Research

    K. Schroeder, C. Gallagher, M. Armstrong, M. Carnie, C. Evers, J. Fleisher, B. Kluger, J. Lamb, S. Seshadri, L. Wilson, M. Feeney, P. Davies (New York, USA)

  • Patient and caregiver satisfaction of video-assisted telenursing in patients treated with LCIG

    T. Gurevich, A. Evans, G. Kägi, D. Koziorowksi, L. Bergmann, JC. Parra Riaza, O. Sanchez-Soliño, J. Slawek (Tel Aviv, Israel)

  • Patient-specific multivariate gray matter volumetric distance to predict disease severity in Parkinson’s disease

    A. Vijayakumari, H. Fernandez, B. Walter (Cleveland, USA)

  • Patient-Specific Outcomes of Transcutaneous Afferent Patterned Stimulation with Varying Frequencies for Essential Tremor and Parkinson’s Disease

    A. Kent, H. Kim, D. Khosla, K. Rosenbluth (Foster City, USA)

  • Patients with Parkinson’s Disease Share a Unique Olfactory Perceptual Fingerprint

    M. Andelman-Gur, K. Snitz, A. Ravia, N. Hezi, A. Ezra, D. Klepikov, T. Gurevich, N. Sobel (Rehovot, Israel)

  • Pattern of non-motor symptoms in Parkinson’s disease: A prospective observational study

    S. Mudassir, A. Rai, A. Ranjan, A. Kumar (Patna, India)

  • Patterns of early-phase 18F-FP-CIT PET images and the risk of dementia conversion in Parkinson’s disease

    S. Chung, P. Lee, Y. Kim, Y. Sohn (Yongin-si, Republic of Korea)

  • Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations

    J. Agin-Liebes, R. Hickman, J. Vonsattel, X. Flowers, P. Faust, R. Mayeux, K. Marder, S. Przedborski, S. Fahn, M. Surface, R. Alcalay (New York, USA)

  • PD GENEration Clinical Phase: Genetic Diagnostic Yield and Clinical Characteristics

    L. Cook, J. Verbrugge, T. Schwantes-An, M. Nance, A. Naito, K. Marder, M. Schwarzschild, T. Simuni, A. Wills, A. Hall, J. Schulze, P. Hodges, C. Casaceli, L. Heathers, K. Ghosh, J. Beck, R. Alcalay (Indianapolis, USA)

  • PD-MCI is frequent in candidates to subthalamic deep brain stimulation and is associated with structural brain alterations

    K. Dujardin, Q. Devignes, S. Daoudi, R. Viard, R. Lopes, N. Betrouni, G. Kuchcinski, AS. Rolland, JC. Corvol, D. Devos (Lille, France)

  • PD+: A comprehensive, user-friendly mobile application for clinicians treating Parkinson’s Disease

    E. Shah, T. Khachatryan, N. Phielipp, S. Isfahani (Orange, USA)

  • Pedunculopontine Nucleus Structural Integrity and Freezing of Gait in Parkinson’s Disease Patients

    K. Yen, R. Camicioli, M. Gee, F. Ba (Edmonton, Canada)

  • Perceive: A data extraction and analysis toolbox for brain signals from sensing enabled deep brain stimulators

    WJ. Neumann (Berlin, Germany)

  • Perception-action binding in patients with functional movement disorders

    J. Moyé, F. Chwolka, T. Paulus, S. Zittel, J. Verrel, T. Bäumer, A. Münchau, A. Weissbach (Lübeck, Germany)

  • Perceptions of Palliative Care in Huntington’s Disease

    B. Heffernan, L. Seeberger, E. Forbes, J. Shattuck, M. Cook, R. Ayele (Aurora, USA)

  • Perceptions of persons with Parkinson’s disease towards telemedicine as an alternative mode of consultation: An International Pre-Implementation Survey

    O. Ojo, N. Okubadejo, J-H. Ahn, J. Youn, A. Shalash, E. Hamid, A. Cardozo, A. Garcia-Bustillo, Z. Mari, M. Spindler, E. Cubo (Idi-araba, Nigeria)

  • Performance of oral diadochokinesis in Parkinson’s Disease motor subtypes

    V. Dos Santos, R. Rothe-Neves,, A. Bressanelli, I. Klein, M. Olchik (Porto Alegre, Brazil)

  • Performance of Parkinson´s disease cognitive scale rating scale (PD-CRS) after 2 years Subthalamic nucleus deep brain stimulation. Comparison with Mattis Dementia Rating Scale (MDRS) and Mini-Mental State Examination (MMSE)

    C. García-Sánchez, C. Pons, N. Grunden, B. Pascual-Sedano, A. Gironell, R. Rodriguez, J. Kulisevsky (Barcelona, Spain)

  • Personalization of deep brain stimulation using local field potentials to drive adaptive DBS: a case series

    H. Kamo, G. Oyama, T. Brionne, D. Kamiyama, A. Umemura, H. Iwamuro, A. Bovet, G. Spriano, A. Singer, P. Di Stefano, N. Hattori (Tokyo, Japan)

  • Personalized Medicine: Assessing the Needs of People with Young-Onset Parkinson’s Disease

    B. Mcdaniels, I. Subramanian, S. Kurian, S. Chitnis (Denton, USA)

  • Perturbation-based balance training in individuals with Parkinson’s disease and freezing of gait

    DB. Coelho, C. Ribeiro Souza, J. ávila Oliveira, L. Rezende, P. Takazono, C. Silva-Batista, L. Teixeira (São Bernardo Campo, Brazil)

  • Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease

    J. Potheegadoo, F. Bernasconi, O. Blanke (Geneva, Switzerland)

  • Phantom Pregnancy – A Novel Impulse Control Behaviour in Parkinson’s Disease: A Case Report

    H. Martin, L. Teare (Coventry, United Kingdom)

  • Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease

    L. Kou (Wuhan, China)

  • Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)

    R. Kumar, D. Claassen, A. Mongan, A. Grover, B. Hoehn, P. Lin, R. Arnold, E. Cahir-Mcfarland, T. Yednock, S. Keswani (Englewood, USA)

  • Phase-amplitude coupling between beta power and high frequency oscillations as a sensitive marker of parkinsonian state.

    M. Bočková, M. Lamoš, P. Daniel, M. Baláž, J. Chrastina, I. říha, I. Rektor (Brno, Czech Republic)

  • PHENOTYPIC DESCRIPTION OF TWO UNREPORTED FAMILIES WITH ANO3 DYSTONIA

    A. Trinchillo, G. de Joanna, M. Esposito (Naples, Italy)

  • Phenotypical and treatment response heterogeneity in a cohort of normal pressure hydrocephalus patients

    A. Di Maio, G. Lazzeri, F. Arienti, F. Ruggiero, F. Mameli, A. Di Fonzo, G. Franco (Milan, Italy)

  • Phosphorylated α-synuclein at serine residue 129 decreased in Parkinson’s disease patients taking 250mg of daily niacin for six months

    C. Wakade, M. Seamon, S. Purohit, J. Morgan, R. Chong (Augusta, USA)

  • Physical activity and incidence of Parkinson’s disease in French women from the E3N cohort study

    B. Portugal, F. Artaud, I. Degaey, E. Roze, G. Severi, M. Canonico, C. Proust-Lima, A. Elbaz (Villejuif, France)

  • Physician satisfaction from continuous telemonitoring in Parkinson’s disease

    A. Ntanis, G. Rigas, K. Tsamis, A. Tsakanika, F. Kanellos, S. Konitsiotis, D. Fotiadis (Ioannina, Greece)

  • Pilot case on the use of transcranial pulsed current stimulation(tPCS) in a patient with cervical dystonia(CD)

    JR. Chai, S. Bansal, D. Aur, O. Samotus, M. Jog (London, Canada)

  • Pilot study of narrative medicine (NM) interventions in facilitating advance care planning (ACP) in Parkinson’s disease (PD): a feasibility study

    J. Jiao, B. Lobb, A. Hiller (Portland, USA)

  • Pilot study to investigate the use of in-clinic sensing to identify optimal stimulation parameters for deep brain stimulation therapy in Parkinson’s disease

    S. Lewis, S. Ojemann, D. Kramer, L. Hirt, E. Radcliffe, M. Case, A. Becker, R. Raike, J. Thompson, D. Kern (Boulder, USA)

  • Ping Pong as a sport-based intervention to increase physical activity in people with Parkinson’s Disease

    J. Domingos, J. Fernandes, J. Dean, C. Godinho (Monte de Caparica, Portugal)

  • PLA2G6-related dystonia-parkinsonism in identical twins manifesting at an advanced age: a case report and review of the literature.

    D. Sugar, K. Kompoliti (Chicago, USA)

  • Plasma Alzheimer’s disease biomarkers and cognitive progression in Parkinson’s disease

    A. Pilotto, NJ. Ashton, A. Lupini, B. Battaglio, S. Gipponi, E. Cottini, I. Grossi, A. Salvi, G. de Petro, M. Pizzi, K. Blennov, M. Gonzalez, D. Aarsland, H. Zetterberg, A. Padovani (Brescia, Italy)

  • Plasma biomarkers of disease progression in Parkinson’s disease

    A. Lupini, N. Ashton, A. Pilotto, B. Battaglio, C. Zatti, S. Gipponi, E. Cottini, I. Grossi, A. Salvi, G. de Petro, M. Pizzi, K. Blennow, H. Zetterberg, A. Padovani (Brescia, Italy)

  • Plasma p-Tau181 and p-Tau231 in Parkinson’s Disease

    MC. Gonzalez, NJ. Ashton, A. Pilitto, A. Padovani, B. Fernandes Gomes, DA. Tovar-Rios, F. Blanc, A. Lemstra, C. Paquet, C. Abdelnour, M. Boada, L. Bonanni, R. Vandenberghe, K. Blennow, H. Zetterberg, D. Aarsland (Stavanger, Norway)

  • Plasma p-tau181 is increased in Lewy body dementia and relates to cognitive performance

    N. Hannaway, A. Heslegrave, R. Bhome, I. Dobreva, H. Zetterberg, R. Weil (LONDON, United Kingdom)

  • Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease

    L. Batzu, S. Rota, A. Hye, A. Heslegrave, D. Trivedi, L. Gibson, C. Farrell, P. Zinzalias, A. Rizos, H. Zetterberg, K. Ray Chaudhuri, D. Aarsland (London, United Kingdom)

  • Polymorphisms in Prosaposin gene are associated with familial and early-onset Parkinson’s disease: A case-control association study and meta-analysis

    YT. Chu, MC. Kuo, YA. Su, RM. Wu (Taipei, Taiwan)

  • Polypharmacy and drug-related problems in geriatric patients with Parkinson’s Disease

    PV. Menon, CY. Lee, CH. Tan, S. Kumar Seetharaman (Singapore, Singapore)

  • Pons and middle cerebellar peduncle diameters are diagnostic of Multiple System Atrophy of the Cerebellar Type (MSA-C)

    C. Stephen, M. Vangel, A. Gupta, J. Macmore, J. Schmahmann (Boston, USA)

  • PONTINE AND EXTRAPONTINE MYELINOLYSIS PRESENTING AS ACUTE PARKINSONISM

    Y. Sucullu Karadag, T. Saltoğlu, B. Gecer (Ankara, Turkey)

  • Pooled safety analysis of incobotulinumtoxinA in the treatment of neurological disorders in adults

    C. Comella, M. Hast, A. Hanschmann (Chicago, USA)

  • POOR SLEEP QUALITY AND OBESITY IN PATIENTS WITH PARKINSON’S: PRELIMINARY RESULTS OF A COHORT STUDY

    A. Ferrari Aquino, J. Garza Marichalar, D. Ortiz Zacarías, I. Estrada Bellmann, B. Chávez Luévanos (Monterrey, Mexico)

  • Post anoxic chorea: a rare complication after anoxic brain injury

    C. Wantaneeyawong, K. Thiankhaw (Chiang Mai, Thailand)

  • Post deep brain stimulation cognitive decline in GBA-related Parkinson’s disease

    C. Weill, A. Gallant, E. Linetsky, Z. Israel, D. Arkadir (jerusalem, Israel)

  • Postural Instability in Parkinson’s Disease: Phenotypic data from The Cincinnati Cohort Biomarker Program

    K. Duque, J. Abanto, R. Bode, N. Gregor, F. Pariona, J. Hernandez, A. Espay, L. Marsili (Cincinnati, USA)

  • Postural tremors due to a cystic thalamic low-grade glioma treated by stereotactic aspiration

    M. Agrawal, S. Bhaskar, A. Arora, S. Panda, M. Garg, D. Jha (Jodhpur, India)

  • PP1α negatively regulates D2 receptor mediated cadmium induced motor dysfunctions: protective potential of Quercetin.

    R. Gupta, R. Shukla, V K. Khanna (LUCKNOW, India)

  • Preclinical Characterization of Suvecaltamide for Essential Tremor

    E. Brigham, N. Shanks, S. Markova, L. Tan, J. Kramer, D. Huffman, M. Lee (Palo Alto, USA)

  • Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)

    C. Vermeiren, A. Ates, F. Bouzom, A. Delaunois, M. Gillard, B. Kenda, A. Ousset, L. Provins, D. Skolc, A. Valade, M. Vanmeulder, M. Wood, Y. Lamberty (Braine-l'Alleud, Belgium)

  • Predicting cognitive decline using neuropsychiatric symptoms in prodromal Lewy body disease.

    L. Wright, P. Donaghy, D. Burn, J-P. Taylor, J. O'Brien, A. Yarnall, F. Matthews, M. Firbank, A. Thomas, R. Lawson (Newcastle upon Tyne, United Kingdom)

  • Predicting the development of dementia in patients with Parkinson’s disease by comparing neurosteroids in the blood level

    DI. Okhunova, G. Sattarovna, A. Babokhujaev (Tashkent, Uzbekistan)

  • Prediction of early-stage Parkinson’s disease using connectivity and morphometry of the striatum

    D. Henadeerage Don, E. Alushaj, N. Handfield-Jones4, A. Khan, P. Macdonald (London, Canada)

  • Predictive factors for a favorable STN-DBS outcome in Parkinson’s Disease: the role of axial symptoms

    C. Ledda, C. Artusi, G. Imbalzano, M. Bozzali, M. Rizzone, A. Romagnolo, M. Zibetti, L. Lopiano (Turin, Italy)

  • Predictors of loss to follow-up three years after inclusion in a prospective longitudinal cohort study in people with early Parkinson’s disease

    C. Pauly, AM. Hanff, G. Aguayo, A. Rauschenberger, A. Leist, C. Mccrum, M. Zeegers, R. Krüger (Luxembourg, Luxembourg)

  • Predictors of relapse in impulse control disorders in patients with Parkinson’s disease.

    L. Gaibor, D. Vazquez, H. Estrada (CDMX, Mexico)

  • Predictors of short-term anxiety outcome after subthalamic stimulation in Parkinson’s Disease

    A. Sauerbier, V. Stopic, J. Herberg, P. Loehrer, K. Ashkan, A. Rizos, S. Jost, JN. Petry-Schmelzer, S. Heil, A. Gronostay, M. Barbe, V. Visser-Vandewalle, J. Evans, C. Nimsky, G. Fink, A. Antonini, P. Martinez-Martin, M. Silverdale, D. Weintraub, A. Schrag, K. Ray Chaudhuri, L. Timmermann, H. Dafsari (Cologne, Germany)

  • Predictors of the change in burden and strain among caregivers of Parkinson’s disease patients

    C. Cores Bartolomé, D. Santos García, T. Fonticoba, M. Feal Painceiras, E. Suarez Castro, C. Martinez Miro, S. Jesus Maestre, M. Aguilar, P. Pastor, L. Planellas, M. Cosgaya, J. Garcia Caldentey, N. Caballol, I. Legarda, J. Hernandez Vara, I. Cabo, L. Lopez Manzanares, I. Gonzalez Aramburu, MA. Avila Rivera, V. Gomez Mayordomo, V. Nogueira, V. Puente, J. Garcia-Soto, C. Borrue, B. Solano Vila, M. Alvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo Padilla, JC. Martinez Castrillo, P. Sanchez Alonso, MG. Alonso Losada, MI. Morales Casado, I. Gaston, J. Kulisevsky, M. Blazquez Estrada, M. Seijo, J. Ruiz Martinez, C. Valero, M. Kurtis, O. de Fabregues, J. Gonzalez Ardura, R. Alonso Redondo, C. Ordas, LM. Lopez Diaz, D. Mcafee, P. Martinez Martin, P. Mir (A CORUÑA, Spain)

  • Preferences for discussing sexual health concerns

    G. Bronner, S. Peleg Nesher, Y. Manor, A. Rosenberg, S. Naor, A. Ezra, R. Mallin, R. Hurvitz Alon, T. Gurevich (Tel Aviv, Israel)

  • Preliminary data on multimodal approach for early characterization of Parkinson’s disease (PD) and Multiple System Atrophy (MSA), a prospective study with connected insoles

    F. Marchand, L. Farid, J. Labreuche, R. Viard, L. Defebvre, D. Devos, A. Mathieu, L. Kjaersgaard, AK. Berger, D. Meulien, V. Terebaite, JC. Brasen, C. Moreau (LILLE, France)

  • Preliminary estimates of the effects of deep brain stimulation on gait kinematics in Parkinson disease and essential tremor.

    P. Testini, G. Skelton, D. Bernhard, S. Miocinovic, P. Aia, C. Buetefisch, L. Higginbotham, L. Scorr, S. Triche, J. Mckay, C. Esper (Atlanta, USA)

  • Preliminary real-world surgical data collection in RAD-PD

    J. Jimenez-Shahed, A. Berg, M. York, J. Kirk, M. Siddiqui, J. Schwalb, J. Mcinerney (New York, USA)

  • Preliminary results on the cognitive profile in prodromal Parkinson’s disease – a prospective study

    L. Pauly, M. Hansen, C. Pauly, A. Leist, R. Krüger (Strassen, Luxembourg)

  • Preliminary Verification of a Kinect-based System for Evaluating Postural Abnormalities in Patients with Parkinson’s Disease

    RH. Hong, Z. Wu, TY. Zhang, ZY. Zhang, XY. Su, Y. Jin, YC. Gao, LZ. Pan, HP. Zhi, Q. Guan, LJ. Jin (Shanghai, China)

  • Prepulse inhibition of the blink reflex in functional movement disorders

    L. Nováková, P. Sojka, D. Voženílek, E. Růžička, T. Serranová (Praha, Czech Republic)

  • Pressure Sensor Insole Gait Assessment for Parkinson’s Disease patients: A pilot study

    Z. Kefalopoulou, C. Chatzaki, V. Skaramagkas, E. Chroni, N. Tachos, DI. Fotiadis, M. Tsiknakis (Patras, Greece)

  • Presynaptic dopamine compartmentalization defects initiate auxilin-mediated parkinsonism

    D J. Vidyadhara, M. Somayaji, N. Wade, H. Zhao, S. Narayanan, J. Gupta, T. Lam, D. Sames, L. Greene, D. Sulzer, S. Chandra (New Haven, USA)

  • Prevalence and distribution of disease-associated alpha-synuclein in a homeless population

    N. Visanji, K. Danics, G. Kovacs (Toronto, Canada)

  • Prevalence of GBA parkinsonism in Slovak Parkinson’s disease population

    A. Lacková, V. Han, P. Pavelekova, Z. Gdovinova, M. Skorvanek, K. Kulcsarova, M. Ostrozovicova, T. Lorincova, P. Bauer, CH. Beetz, S. Oppermann, E. Tusay, B. Kovacova, B. Stasko, E. Petro, S. Bohacova (Košice, Slovakia)

  • Prevalence of Movement Disorders After Acute Stroke: a Large Prospective Cohort Stroke Study

    MS. Rocha, L. Alves, J. Tatsch, H. Bezerra, J. Freitas, I. Torres, J. de Paula, P. Marques, P. Matos (SAO PAULO, Brazil)

  • Prevalence of Parkinson’s disease and Atypical Parkinsonisms in Colombia: Data from the national health registry 2016-2021

    G. Rincón, J. Torres-García, C. Pantoja-Ruiz, D. Rosselli (Bogotá, Colombia)

  • Prevalence of sleep disorders in Parkinson’s disease patients at a Brazilian movement disorders center in 2022

    L. Castanheira, C. Lobo, I. Oliveira, L. de Almeida, G. Valença (Salvador, Brazil)

  • Prevalence of sleep disorders symptoms in essential tremor

    D. Vazquez-Guevara, C. Terán-Padilla, A. Abundes-Corona, A. Cervantes-Arriaga, L. Gaibor-Noboa, H. Estrada-Rodriguez, M. Rodríguez-Violante (Mexico city, Mexico)

  • Prevalence, clinical and neuropsychiatric aspects of Sleep Disorders in Parkinson’s disease: a meta-analysis

    G. Maggi, F. Cerciello, I. Obeso, G. Santangelo (Caserta, Italy)

  • Prevention and management of Deep Brain Stimulation (DBS) surgical site infections (SSI) – multicentre survey of UK practice.

    S. Perides, J. Candelario-Mckeown, M. Kaminska, H. Hasegawa (London, United Kingdom)

  • Priorities of PD patients for treatment of cognitive-driven ADL impairment

    I. Liepelt-Scarfone, M. Bentele, S. Becker, C. Altmann, E. Schaeffer, K. Michaelis, S. Solbrig, K. Brockmann (Tübingen, Germany)

  • Probable Four-repeat tauopathy criteria in Corticobasal Syndrome: diagnostic accuracy, clinical features and imaging biomarkers

    J. Parmera, C. Carneiro, M. Oliveira, P. Barbosa, C. Buchpiguel, R. Nitrini, E. Barbosa, S. Brucki, A. Coutinho (São Paulo, Brazil)

  • Prodromal non-motor symptoms in Multiple System Atrophy. Differences between cerebellar and parkinsonian phenotypes.

    P. Millar Vernetti, H. Kaufmann, JA. Palma (New York, USA)

  • Profile and neural correlates of language disintegration in early Huntington’s disease

    S. Martinez-Horta, A. Puig-Davi, F. Sampedro, J. Perez-Perez, J. Matias-Guiu, A. Horta-Barba, J. Pagonabarraga, M. Diez-Cirarda, L. Fernandez-Romero, M. Yus, F. Cuetos, J. Kulisevsky (Barcelona, Spain)

  • Profiling the biochemical lysosomal activities in blood of patients with LRRK2 G2019S associated Parkinson’s disease

    K. Basharova, A. Bezrukova, I. Miliukhina, A. Timofeeva, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

  • Programming algorithm for the management of speech impairment in STN-DBS for Parkinson’s disease

    B. Swinnen, V. Lotfalla, J. Dijk, V. Odekerken, R. Schuurman, R. de Bie, M. Beudel (Amsterdam, Netherlands)

  • Programming Time and the Use of a Visualization Tool for DBS Programming of a Multiple­-Source, Constant-Current System

    J. Aldred, T. Zesiewicz, M. Okun, J. Ramirez-Castaneda, L. Verhagen-Metman, C. Luca, R. Ramdhani, J. Durphy, Y. Bezchlibnyk, K. Foote, S. Sani, A. Papanastassiou, J. Carlson, J. Jagid, D. Weintraub, J. Piltitsis, Y. Pei, R. Jain (Spokane, USA)

  • Progress of the UK Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial

    A. Bamford, S. Neumann, J. Taylor, G. Young, S. Emmett, W. Hollingworth, A. Whone, D. Steeds, C. Metcalfe, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

  • Progressive ataxia and palatal tremor due to a novel heterozygous GRIN2A mutation

    E. Ardila, G. Kägi, F. Brugger (St. Gallen, Switzerland)

  • Progressive Supranuclear Palsy (PSP) Vs Parkinson’s Disease (PD) – Whether Frontal Assessment Battery (FAB) Can Differentiate

    M. Kulsum, D. Das, S. Ananad (Kolkata, India)

  • Pronunciation characteristics of patients with Parkinson’s disease based on sustained vowel speech

    Y. Wen, X. Zou (Chengdu, China)

  • Prospective, Multicenter, International Registry of Deep Brain Stimulation for Essential Tremor

    G. Deuschl, R. Schuurman, G. Loret, N. Kovacs, M. Blázquez Estrada, F. Clement, J. Il Lee, L. Chen, R. Jain (Kiel, Germany)

  • Prospective, Multicenter, Real-World Outcomes Study with Directional Deep Brain Stimulation Systems in the Treatment of Parkinson’s Disease

    M. Okun, K. Foote, T. Zesiewicz, Y. Bezchlibnyk, A. Papanastassiou, J. Ramirez-Castaneda, J. Carlson, J. Aldred, V. Krishna, A. Merola, C. Luca, J. Jagid, J. Durphy, L. Verhagen-Metman, S. Sani, S. Ojemann, D. Kern, D. Weintraub, R. Ramdhani, A. Siadati, B. Sundaram, C. Zhao, D. Martinez, M. Siddiqui, S. Tatter, J. Wang, R. Jain (Gainesville, USA)

  • Protective approach targeting NF-kB/ Nrf2 signaling and neuroinflammation using Apigenin in LPS induced Parkinsonism in experimental rats

    S. Singh (Moga, India)

  • Protective effects of Hibiscus sabdariffa extracts in 6-hydroxydopamine-lesioned parkinsonism.

    A. Hamadjida, G. Ndji Otto, MK. Mingoas Kilekoung (bertoua, Cameroon)

  • Protective mechanism of melatonin via heat shock protein in the MPP+-induced in vitro Parkinson’s disease model

    YJ. Jung, E. Oh, A. Kim, H. Choi (Daejeon, Republic of Korea)

  • Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in enriched iPSC-derived human midbrain dopaminergic neurons

    G. Virdi, M. Choi, J. Evans, S. Strohbuecker, M. Horrocks, R. Patani, S. Gandhi (London, United Kingdom)

  • Pseudo-INO in PSP? – A Case Report

    DK. Khandelwal, VM. Mathur (Jaipur, India)

  • Pseudodystonia due to Palmaris Brevis Syndrome: Case Report

    D-Y. Liou, A. Alamoudi, D. Preston, C. Kilbane (Cleveland, USA)

  • Psychiatric evaluation according to Brief Psychiatric Rating Scale-Expanded in patients with Parkinson’s disease

    N. Ben Ali, M. Ben Mahmoud, E. Derbel, H. Jamoussi, S. Fray, M. Fredj (Tunis, Tunisia)

  • Psychometric characteristics of the Neuropsychiatric Fluctuation Scale

    E. Schmitt, B. Debu, A. Kistner, A. Castrioto, V. Fraix, M. Bouvard, E. Moro (grenoble, France)

  • Psychometric properties and construct validity of the Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) in Colombia.

    B. Muñoz-Ospina, H. Clavijo-Moran, D. álvarez-García, G. Pinilla-Monsalve, J. Orozco Velez (Cali, Colombia)

  • Psychosis in Parkinson’s disease and polymorphisms of the HOMER1 and COMT genes: Is there an association?

    A. Lenka, S. Vadivel, R. Christopher, A. Shyam Sundar, S. Hegde, R. Yadav, P. Pal (Bangalore, India)

  • Psychotherapy as a potential treatment for neuropsychiatric startle syndromes of Latah – a case report

    GB. Eow, TT. Lim, K. Tan, YY. Beh (Georgetown, Malaysia)

Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley